RediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability. It is based on the technology of SNP (Single Nucleotide Polymorphisms), which is the standard method for the analysis of abnormal chromosomal structures formed as a result of the Homologous Recombination Deficiency. Combined with the analysis of mutations of the BRCA1 / 2 genes in the tumor, it gives us a comprehensive picture of the functionality of the HR pathway.
The RediScore® test is recommended for all patients with ovarian cancer, but also where the use of PARP inhibitors is under investigation for treatment or maintenance treatment of the patient.
It has now been proven by a plethora of clinical studies that about 50% of ovarian cancer patients could benefit from the administration of PARP inhibitors. These include patients with:
Since 2014, four PARP inhibitors (PARPi) have been approved by the FDA: Olaparib, Niraparib, Rucaparib, and Talazoparib. Their administration has been approved for 4 types of cancer: ovarian, prostate, pancreatic and breast cancer.
HRD (Homologous Recombination Deficiency) means the inability of the cell to repair its damage through the homologous recombination pathway. The presence of genomic instability is indicative of the HR pathway insufficiency.
For the calculation of HRD, three biological parameters are used (‘’genomic scars’’):
BRCA1 and BRCA2 genes play an essential role in the correct functioning of the homologous recombination. Tumors bearing germline and / or somatic mutations in these genes have a deficiency with the homologous recombination pathway. (HRD).
The determination of the Homologous Recombination Deficiency (HRD) is performed via: